Trial Details

Not recruiting
Basic Information
Clinical ID c3123
Identifier NCT01981616
Trial Title A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single Dose Study in Healthy Subjects to Determine the Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
Trial URL Visit Original Page
Study Information
Study Results

Yes
Conditions Inflammatory Bowel Disease;Inflammatory Bowel Disease;Inflammatory Bowel Disease;Inflammatory Bowel Disease
Interventions Drug: Vedolizumab;Drug: Placebo;Biological: Hepatitis B vaccine;Biological: Oral cholera vaccine;Drug: Vedolizumab;Drug: Placebo;Biological: Hepatitis B vaccine;Biological: Oral cholera vaccine;Drug: Vedolizumab;Drug: Placebo;Biological: Hepatitis B vaccine;Biological: Oral cholera vaccine;Drug: Vedolizumab;Drug: Placebo;Biological: Hepatitis B vaccine;Biological: Oral cholera vaccine
Participant Information
Sponsor Millennium Pharmaceuticals, Inc.
City -
Country/Region United Kingdom
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT
Study Design
Study Type Interventional
Phase PHASE1
Time Information
Start Date 2025-04-24
Primary Completion Date 2014-07-21
Completion Date -